1.24
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
| Volume | 5,129 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Sunshine Biopharma Inc | SBFM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.24 | 08:01:15 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.24 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 42 | 5,129 | - | 1.03 - 9.87 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:04:02 | 3 | $ 1.25 | USD |
Period:
Draw Mode:
Sunshine Biopharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 22.66M | 18.89M | 18.53M | $ 228.43k | $ - | -4.79 | -1.30 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 25.00k | 0.90% |
Sunshine Biopharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SBFM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.13 | 1.50 | 1.09 | 1.23 | 1,235,507 | 0.11 | 9.73% |
| 1 Month | 1.12 | 1.85 | 1.03 | 1.30 | 2,640,616 | 0.12 | 10.71% |
| 3 Months | 1.92 | 2.1977 | 1.03 | 1.32 | 1,751,500 | -0.68 | -35.42% |
| 6 Months | 2.75 | 9.87 | 1.03 | 5.11 | 6,587,029 | -1.51 | -54.91% |
| 1 Year | 2.75 | 9.87 | 1.03 | 5.11 | 6,587,029 | -1.51 | -54.91% |
| 3 Years | 2.75 | 9.87 | 1.03 | 5.11 | 6,587,029 | -1.51 | -54.91% |
| 5 Years | 2.75 | 9.87 | 1.03 | 5.11 | 6,587,029 | -1.51 | -54.91% |
Sunshine Biopharma Description
| Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). |